SUSTAIN trial programme: difference between revisions
Diff·revision 14 → 15·21:08, 30 May 2025
Difference between revision 14 and revision 15 of SUSTAIN trial programme. 5 lines changed; the page grew by 541 bytes.
| Revision 14 — 09:12, 24 Apr 2025 StyleSheetSybil (talk) attribute the subgroup finding as exploratory 4,187 bytes ±0 | Revision 15 — 21:08, 30 May 2025 ExenatideEzra (talk) rm the cross-trial comparison; the populations are not comparable 4,728 bytes +541 | ||
|---|---|---|---|
| 34 | The [[SELECT trial|SELECT]] trial subsequently addressed cardiovascular outcomes in a different population and with a dedicated superiority design.{{r|lincoff2023}} | 34 | The [[SELECT trial|SELECT]] trial subsequently addressed cardiovascular outcomes in a different population and with a dedicated superiority design.{{r|lincoff2023}} |
| 35 | 35 | ||
| + | 36 | == Relationship to the obesity programme == | |
| + | 37 | SUSTAIN and [[STEP trial programme|STEP]] study the same molecule at different doses in different populations, and their results are not interchangeable. The diabetes doses are 0.5 and 1.0 mg; the obesity dose is 2.4 mg.{{r|sorli2017}} | |
| + | 38 | ||
| + | 39 | This is the source of a persistent confusion when SUSTAIN 7 or the tirzepatide comparison in SURPASS-2 are cited as though they compared maximal doses. They did not, and the distinction changes what the comparison means. See [[Tirzepatide]].{{r|lincoff2023}} | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |